Study Cancer Immunotherapy with our High Quality Antibodies
PD-1 and LAG-3 are negative regulatory proteins with similar roles found on the surface of non-functional CD8 T cells. It has been found that PD-1 and LAG-3 are markers of exhaustion that are upregulated in several tumor types. Upregulation of these proteins suppress the immune response which allows for uncontrolled tumor growth. Prior research has shown blocking these immune checkpoints with inhibitors have an anti-tumor effect without overt signs of autoimmunity. Antibodies such as our PD-1 Recombinant monoclonal antibody (RMPD1-1) and our LAG-3 (human) monoclonal antibody (17B4) are being researched as new potential immunotherapy targets for cancer.. |
PD-1 Recombinant monoclonal antibody (RMPD1-1)
- Programmend cell death-1, CD279
- High purity
- Expressed on activated T-cells, B-cells, and myeloid cells
- Potentially superior diagnostic marker in angioimmunoblastic lymphoma
|
LAG-3 (human) monoclonal antibody (17B4)
- Lymphocyte activation gene-3, FDC protein, CD223
- High purity
- Binds to MHC class II molecules but with higher affinity than CD4
- LAG-3 has been suggested as a serological marker of Th1 responses
| New Immunotherapy Target Identified
PD1/PD-L1 interaction ensures that activation of the immune system occurs at the appropriate time and minimizes the possibility of chronic autoimmune inflammation. Upregulation of PD-L1 may allow cancers to evade the immune response. Many immune-oncology therapies use PD-L1 inhibitors with great success. PD-1 can trick your immune system into overlooking cancer cells as normal cells. Recently, a new report identified another protein, CMTM6, which stabilizes PD-L1 and increases the ability of cancer cells to avoid being destroyed by inhibiting the immune response.
| |